A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Active, not recruiting · Phase 3 · NCT05559359
Conditions: Atopic Dermatitis, Eczema
At a glance
- Research payments reported, 2025
- $380,203
- U.S. investigators named
- 20
- Sites paid
- 23
- Planned or actual enrollment
- 377
About the trial
- Sponsor
- Eli Lilly and Company (with Dermira, Inc.)
- Tested
- Lebrikizumab (drug), Placebo (drug), Topical Corticosteroid (TCS) (drug)
- Dates
- Started 2022-10-18; completion 2026-12
- Results posted
- Not yet
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
From ClinicalTrials.gov, last updated 2026-07-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $380,203 in research payments for this study in 2025 (32 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Weily Soong, M.D. Specialist · Birmingham, AL
- Scott M. Dinehart, M.D. Mohs Surgery · Little Rock, AR
- Harper Price, M.D. Dermatology · Phoenix, AZ
- Jennifer Ornelas Dermatology · Sacramento, CA
- Howard L. Sofen, M.D. Dermatology · Los Angeles, CA
- Jun Lu, MD Dermatology · Farmington, CT
- Seth B. Forman, MD Dermatology · Tampa, FL
- Elizabeth A. Swanson, M.D. Dermatology · Meridian, ID
- Amy S. Paller, MD Dermatology · Chicago, IL
- Lee S. Clore JR., M.D. Allergy & Immunology · Owensboro, KY
- Brent M. Boyce, M.D. Dermatology · Sebewaing, MI
- Christofer N. Buatti, D.O. Dermatology · Auburn Hills, MI
- Jeffrey G. Leflein, MD Allergy & Immunology · Ypsilanti, MI
- Brian Simmons, MD Dermatology · Lebanon, NH
- Craig A. Rohan, MD Dermatology · Wright Patterson Afb, OH
- Scott L. Gottlieb, M.D. Dermatology · Exton, PA
- Lara Wine Lee, M.D. Dermatology · Charleston, SC
- John C. Browning, MD Dermatology · San Antonio, TX
- Jiade Yu, MD Dermatology · Richmond, VA
- Kristen E. Holland, MD Dermatology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dermatology Research Associates Inc $86,533
- Osman Dermatology $59,126
- Medical University of South Carolina $50,867
- Medical College of Wisconsin Inc $33,673
- Massachusetts General Hospital $31,920
- Clinical Research Ctr of Alabama, LLC $20,725
- Allergy and Asthma Specialists Psc $16,213
- Texas Dermatology and Laser Specialists $11,871
- Oakland Hills Dermatology PC $11,600
- Treasure Valley Medical Research $11,300
- Great Lakes Research Group Inc $10,448
- The Pennsylvania Centre for Dermatology LLC $7,500
- Wright State Physicians Inc $5,676
- Phoenix Children's Hospital, AZ $5,500
- Dartmouth Hitchcock Clinic $5,338
- Forward Clinical Trials Inc $4,500
- Arkansas Research Trials LLC $3,181
- Northwestern University $1,569
- University of Connecticut Health $1,150
- $571
- Dartmouth Hitchcock Medical Center $340
- The Ohio State University $231
- University of South Carolina $196
- Respiratory Medicine Research $175
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.